Off-Label, on Target: New Hope for Children with Inflammatory Bowel Disease

Off-Label, on Target: New Hope for Children with Inflammatory Bowel Disease

Off-label treatments are offering new hope to children battling inflammatory bowel disease (IBD), especially when conventional therapies fall short. A comprehensive new review explores the real-world application of biologics and small molecule drugs originally approved for adults—such as ustekinumab, vedolizumab, upadacitinib, and ozanimod—in pediatric IBD cases. These alternative approaches are showing encouraging results, including higher rates